消积汤联合GP方案治疗晚期非小细胞肺癌临床疗效观察

目的观察消积汤和吉西他滨联合顺铂治疗局部晚期非小细胞肺癌（NSCLC）的临床疗效。方法36例小细胞肺癌患者按数字表的方法随机分为观察组和对照组各18例，观察组全部采用消积汤配合吉西他滨联合顺铂治疗方案，而对照组则采用环磷酰胺、阿霉素、顺铂方案化疗，比较2组患者的临床疗效及不良反应。结果观察组近期总有效率为83．3％（15／18），对照组为66．6％（12／18），2组近期总有效率差异有统计学意义（X2=3．46，P〈0．05）；观察组不良反应发生率低于对照组。结论消积汤配合吉西他滨联合顺铂治疗NSCLC在近期疗效方面较好，而且患者的耐受性更好，有利于改善患者的生存质量。

Clinical curative effect of xiaoji decoction combined gp regimen for advanced non-small cell lung cancer

Objective To observe the clinical curative effect of Xiaoji decoction, gemcitabine combined cisplatin in the treatment of locally advanced non-small cell lung cancer （NSCLC）. Methods Total 36 patients with NSCLC were randomly divided into observation group and control group with 18 cases in each group. The observation group received Xiaoji decoction with gemcitabine and cisplatin treatment, while the control group received cyclophosphamide, doxorubicin and cisplatin. The clinical curative effect and adverse reactions were compared between the two groups. Results The total short-term effective rate was 83.3% （15/18） in the observation group, and 66.6% （12/18） in the control group, the difference between the two groups was statistical significance （ x2 = 3.46, P 〈 0.05 ） ; the incidence of adverse reactions was lower in the observation group as compared to the control group. Conclusion Xiaoji decoction with gemcitabine and cisplatin in the treatment of NSCLC can achieve a better short-term curative effect, and the patient＇s tolerance is better, and the quality of life can be improved.